Figure 5.

LAIR1 blockade inhibits MDSC activity and reactivates T cells in cancer patients. (A) LAIR1⁺% in CD11b⁺ HLA-DR^dim cells as enriched MDSCs isolated from prostate cancer patients as determined by flow cytometry. (B) Representative histograms show that h219-LLG attenuated the T cell suppressive function of MDSCs from prostate cancer patients in a CSFE assay. The CD11b⁺ HLA-DR^dim cells were cocultured with CFSE-stained autologous T cells (E:T =1) for 5 days, treated with 10 µg/mL control or h219-LLG antibodies. (C, D) Quantification of the percentages of proliferative CD4⁺ and CD8⁺ T cells treated as indicated. (E) Enriched MDSCs from a patient with squamous cell carcinoma were cultured without T cells in the presence or absence of collagen, treated with h219-LLG or control antibodies for 5 days. Shown are MFIs of surface CD86 and CD163 as measured by flow cytometry. As Statistical Analysis in Methods stated: * indicates p < 0.05; ** indicates p < 0.01.